ProMIS Neurosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PMN.TO research report →
Companywww.promisneurosciences.com
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
- CEO
- Gail M. Farfel
- IPO
- 2007
- Employees
- 6
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $51.48M
- P/E
- -1.76
- P/S
- 0.00
- P/B
- 1.17
- EV/EBITDA
- 1.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -237.99%
- ROIC
- -68.02%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-12,578,075 · -30.24%
- EPS
- $-1.68 · -0.60%
- Op Income
- $-23,379,912
- FCF YoY
- -83.36%
Performance & Tape
- 52W High
- $11.10
- 52W Low
- $3.34
- 50D MA
- $6.16
- 200D MA
- $6.95
- Beta
- 1.19
- Avg Volume
- 5.31K
Get TickerSpark's AI analysis on PMN.TO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PMN.TO Coverage
We haven't published any research on PMN.TO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PMN.TO Report →